Polycystic ovary syndrome (PCOS) has recently been shown to affect a striking 12%-21% of Australian reproductive-age women, being more common among those who are overweight or of Indigenous background. 1 PCOS can be a frustrating experience for women, a complex syndrome for clinicians and a scientific challenge for researchers, and is a major public health concern.
Although reproductive features are prominent, PCOS has potential for major metabolic consequences, including obesity and related type 2 diabetes mellitus (DM2) as well as cardiovascular disease (CVD), all of which are currently national health priority areas.
2,3 It also has significant mental health and psychological impact, impairing quality of life (QoL).
4,5 Because increased obesity exacerbates incidence, prevalence and severity of PCOS, and weight loss improves reproductive, metabolic and psychological features, lifestyle change should be first-line therapy for PCOS. 6 It is estimated that 70% of Australian women with PCOS remain undiagnosed; 1 clinical practice is inconsistent;
7 psychological issues are under-recognised; 5 and there is little focus on lifestyle and prevention, with most services targeting infertility and costly assisted reproductive technology. Given the prevalence, disease burden, health costs and clear gaps in care, PCOS is highlighted in national policy and has been prioritised by government, with funding for development of a national PCOS evidence-based guideline and translation of evidence into practice. Here, we present a brief general clinical introduction to PCOS, concise guideline algorithms and clinical pathways and a comprehensive summary of the Evidence based guideline for assessment and m a n ag e m e n t o f P C O S ( ava i l a b l e a t h t t p : / / www.managingpco s.org.au/pcos-evidence-basedguidelines).
8 Presentation PCOS has significant and diverse implications, including reproductive (hyperandrogenism, hirsutism, anovulation, infertility), metabolic (insulin resistance [IR] , impaired glucose tolerance, DM2, adverse cardiovascular risk profiles) and psychological features (increased anxiety and depression and worsened QoL). 9 Presentation varies across the life span. Hyperandrogenic features are often most prominent among adolescents, 10 fertility issues most prominent among women in their 20s and 30s, and metabolic challenges most notable after this. 11 The propensity to weight gain and psychological challenges affect all ages, and metabolic features can occur early, especially among those who are overweight. Variations across ethnic groups should also be noted, such as fewer hyperandrogenic dermatological features and more severe metabolic features in Asian women, even without weight gain. Indigenous women appear to have a higher prevalence and severity of PCOS. 1, 12 The clinical presentation of PCOS is outlined in Figure 1 .
Diagnosis and investigations
Diagnosis of PCOS is now largely based on the Rotterdam criteria, 14 which are inclusive of the original National Institutes of Health (NIH) criteria 15 and require two of three key features: oligo-or anovulation, clinical and/or biochemical hyperandrogenism and polycystic ovaries on ultrasound (Figure 2 ). However, as noted, PCOS phenotypes vary widely depending on life stage, genotype, ethnicity and environmental factors, including lifestyle and body weight. Diagnostic investigations must exclude other causes and include thyroid function tests and prolactin and folliclestimulating hormone (FSH) levels. 9 For diagnosis, androgen levels should be measured; however, optimal methodology remains very controversial and is addressed in Section 1. Vaginal ultrasound is often needed for diagnosis where hyperandrogenism and anovulation are not both clearly present. Ultrasound can check for polycystic ovaries and endometrial thickness. However, vaginal ultrasound should be reserved for sexually active women. The role of ultrasound remains controversial for adolescents, among whom a polycystic appearance of the ovaries is very common, potentially leading to overdiagnosis; 16 hence, this area is also covered in the guideline. Other diagnostic investigations are based on clinical discretion.
Screening is also vital to detect PCOS complications and guide prevention and treatment. Comprehensive cardiovascular risk-factor screening, including family history, ethnic group, body mass index (BMI), waist circumference, smoking status, blood pressure, glycaemic status (oral glucose tolerance test [OGTT] ) and lipid profile, is important at diagnosis and should be repeated with a frequency informed by metabolic risk (eg, body weight, age, family history, ethnicity) as outlined in Section 3. Optimal methodology for the routine screening for prediabetes and DM2 has been controversial in PCOS, but because lifestyle change and metformin improve IR in PCOS, and among other at-risk groups these measures have been shown to dramatically reduce progression to diabetes, early detection, including detection of prediabetes, is vital and is addressed in the guideline.
Aetiology
PCOS is an endocrine disorder, the pathophysiology of which remains unclear. Genetic and environmental contributors combine with obesity, ovarian dysfunction and hormonal drivers to contribute to the aetiology of PCOS. 17, 18 The underlying hormonal imbalance may include a combination of increased androgens and/or hyperinsulinaemia secondary to IR (Figure 1 ). Greater understanding of cause has been hampered by a lack of ideal methods to assess either hyperandrogenism or IR. Hyperandrogenism is detected in around 60%-80% of women with PCOS, and IR is a pathophysiological contributor in around 50%-80%. 19 Obesity increases reproductive features -hyperandrogenism, hirsutism, infertility and pregnancy complications -both independently and by exacerbating PCOS. 20, 21 Furthermore, obesity exacerbates the PCOS-related increased risk factors for impaired glucose tolerance, DM2 and CVD, 22 while obesity also affects psychological features of PCOS.
Clinical features
PCOS is a chronic condition that manifests across the life course. Women with PCOS present with psychological, 5, 23 reproductive 24 and metabolic implications. In terms of psychosocial implications, challenges to feminine identity and body image due to obesity, acne, excess hair, infertility and long-term health-related concerns compromise QoL and adversely affect mood and psychological wellbeing. With a higher prevalence and greater severity of depression and anxiety, low self-esteem, negative body image, and psychosexual dysfunction, 5,25 assessment of psychological functioning in women with PCOS is vital. This is relevant to clinical care as mood disturbance, in turn, impairs QoL and adversely affects ability to selfmanage and optimise lifestyle. Optimal approaches to screening and assessment of psychological functioning in PCOS are unknown and recognition is generally poor; hence, this area was prioritised in the guideline (Section 4). If mood disturbance is detected during screening, further assessment and management is required.
Reproductive and reproductive hormonal features are often the best-recognised features in PCOS as they form the basis of the diagnostic criteria.
14 These include clinical and biochemical hyperandrogenism, anovulation, subfertility and polycystic ovaries on ultrasound. A key point is that fertility is not necessarily impaired in all PCOS cases -some women conceive without medical intervention, depending on the severity of the condition. Age and BMI have a critical role in infertility risk in PCOS; therefore, early family initiation (before the age of 30-35 years) combined with maintaining a BMI < 31 kg/m 2 is ideal for increasing the chance of conceiving.
Metabolic features of PCOS include an apparent propensity for excess weight gain, an increased prevalence of prediabetes and DM2, a 5-10-fold risk of progression from prediabetes to DM2 and a 4-7-fold risk of DM2.
11
Cardiovascular risk factors are increased and CVD appears more prevalent among women with PCOS despite inadequate long-term studies to appropriately address this question. 22 In the general population, IR is a predictor of CVD. 26 , 27 Women with PCOS also have an increased prevalence of metabolic syndrome (associated with an increased risk for DM2 and CVD), 28 individual risk factors for CVD and clinical signs of atherosclerosis, 29, 30 which are all exacerbated by obesity. Women with PCOS are Figure 2 . The Rotterdam criteria for diagnosis of polycystic ovary syndrome (PCOS) 14 The Rotterdam criteria are inclusive of National Institutes of Health (NIH) criteria in that a woman diagnosed with PCOS using the NIH criteria will also meet Rotterdam criteria; however, a woman diagnosed with PCOS using Rotterdam criteria may not meet NIH criteria. ◆ summary of an evidence-based guideline S71 MJA 195 (6) · 19 September 2011 Supplement therefore a population at high risk of developing DM2 and CVD. As DM2 and subsequent CVD are the primary cause of death in Australian women, any increase in prevalence will have significant public health implications. It is also important to note that relatives of women with PCOS may have increased risk of diabetes and increased CVD risk factors. Metabolic features are often poorly appreciated in PCOS; hence, recommendations on screening and assessment of DM2 and CVD risk factors are covered in the guideline.
Obesity or excess weight is a major cause of chronic disease in Western countries. In Australia, 56% of the adult population is overweight (BMI у 25 kg/m 2 ) or obese (BMI у 30 kg/m 2 ). In 2007, 31% of women were overweight and 24% of women were obese. Recent data from the Australian Longitudinal Study on Women's Health showed that among 26-31-year-old women, 20.4% were overweight and a further 13.9% were obese. 31 Overall, the proportion of adults who are obese has doubled in the past 20 years. 32 Obesity is now the primary cause of chronic disease among Australian women, with adverse outcomes including DM2 and CVD. 31 Obesity has a specific impact on women's reproductive health, increasing the prevalence and severity of PCOS, infertility, pregnancy complications, gestational diabetes and fetal pregnancy complications, with substantial and escalating economic costs. 33, 34 Indeed, the adverse impact of obesity on fertility, exacerbated by delay in childbearing, is resulting in a significant social, health and economic burden in Australia. 35 Given the dramatic increase in obesity, the guideline addresses weight loss and prevention of weight gain through lifestyle intervention (Section 5).
Management
Therapy should focus on both the short-and long-term reproductive, metabolic and psychological features. It is important to address psychological factors initially to optimise self-efficacy, readiness to change and sustainability of lifestyle interventions as well as to improve QoL. Screening, assessment and treatment of depression and anxiety are vital, and recognition of other aspects of emotional wellbeing, including poor body image, sexual dysfunction, disordered eating and eating disorders -all more common among women with PCOS -is important for improving QoL. Optimal approaches to screening and assessment of emotional wellbeing among women with PCOS remain unclear and are also addressed in this guideline (Section 4). Once recognised, poor emotional wellbeing and mood disorders should be addressed to improve QoL among women with PCOS.
PCOS management should focus on support and education, and needs to strongly emphasise healthy lifestyle, with targeted medical therapy as required. Given the putative aetiological role of IR and obesity in PCOS, prevention of weight gain is important across the life span. Furthermore, among those who are already overweight, multidisciplinary lifestyle intervention aimed at improving IR and aiding weight management is recognised as firstline therapy for most women who are overweight. 6 Modest weight loss of 5%-10% of initial body weight significantly reduces IR and has been demonstrated to ameliorate many of the features of PCOS. 6 Optimal methods for achieving weight loss and prevention of weight gain remain unclear and are a focus of this guideline (Section 5).
Short-term diets rarely lead to permanent weight loss, and lifestyle change requires behavioural change. Healthcoaching principles can be incorporated to optimise readiness to change, and include education and accurate risk perception, which can assist with motivation through education and tailoring the knowledge relevant to the individual. Once ready to change, support is needed to convert this to action with effective strategies including patient-driven goal setting (eg, 5% of body weight loss, small improvements in exercise), so that these incremental changes are seen as achievements. Multidisciplinary involvement in care is often useful in the early stages to support education and behaviour change and is explored further in this guideline (Section 2).
In addition to lifestyle measures, therapy in PCOS can be targeted to specific clinical presentations. Although there is a plethora of options for therapy in PCOS, in this guideline we have focused on the most controversial interventions, where little guidance is currently available. Assessment of mood disorders and emotional wellbeing is prioritised in the guideline, yet treatment is well guided by a range of existing clinical guidance tools. [36] [37] [38] [39] [40] [41] [42] [43] Hirsutism treatment is also guided by a recent and comprehensive international statement, 44 so these areas are not covered in the guideline. Infertility remains a highly controversial area and is covered in detail in the guideline (Sections 6, 7 and 8). DM2 and CVD risk assessment is included (Section 3); yet treatments for these established complications are covered in other specific national evidenced-based guidelines, 45, 46 and have not been reproduced here. Optimal therapy for infertility is one of the most controversial areas of PCOS management and includes lifestyle interventions, medical and surgical ovulation induction, consideration of bariatric surgery for preconception weight loss, and in-vitro fertilisation (IVF). All these areas are covered in the guideline except for IVF therapy, as this was deemed to be of a lower priority than the first-line lifestyle measures and ovulation induction therapies. Potential targeted treatment options for PCOS are summarised in Box 1.
Considerations for Indigenous women with PCOS
The prevalence of PCOS among Indigenous Australian women appears to be as high as 21% by the Rotterdam criteria 12 and the NIH criteria, 50 and increases with rising BMI.
12 In a group of Indigenous women with PCOS, 30.3% were obese and 7.0% had a normal BMI.
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DM2 and obesity are associated with major morbidity among Indigenous women. The National Aboriginal and Torres Strait Islander Health Survey (NATSIHS) found that Indigenous Australians are 1.2 times more likely to be overweight or obese than non-Indigenous Australians, and this disparity is greatest for women. 51 DM2 is the second-commonest cause of mortality and disabilityadjusted life-years (DALY) among Indigenous women.
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The DALY rate ratios (age-standardised to total Indigenous population) for ischaemic heart disease and DM2 among Indigenous women, compared with all Australian women, are 6.6 and 6.3, respectively; and the mortality rate ratio is 5.0 for ischaemic heart disease and 18.9 for DM2.
The risk of metabolic complications is already high among Indigenous women, independent of PCOS; therefore, PCOS can amplify metabolic risk in these women. Given that these metabolic complications are largely preventable, it is important to provide early access to care.
The leading cause of burden of disease among Indigenous women in the NATSIHS was anxiety and depression, accounting for 10% of the burden. 51 Little is known about the prevalence of eating disorders and disordered eating among Indigenous women. Social and cultural factors influence emotional wellbeing, and the challenges facing many Indigenous women are likely to amplify the impact of PCOS on emotional wellbeing. Further research in this area is needed.
Access to culturally appropriate care, services and programs is currently not optimal. Access issues are a key barrier for many Indigenous women, as health services generally, and women's health services in particular, are limited in rural and remote locations. There are many barriers to healthy lifestyles, including the high cost of maintaining a healthy diet in rural and remote locations. Socioeconomic factors, such as poverty and overcrowding, make the use of refrigerators and kitchen equipment to cook healthy food difficult. Lifestyle programs may need to be applied in different ways to engage Indigenous women and incorporate exercise into daily activities, especially in rural and remote locations, due to a lack of service provision and facilities.
Other issues for Indigenous women include that the role of ultrasound in the Indigenous setting is questionable due to limitations in care and access to ultrasound facilities and service provision in rural and remote locations; and there may be cultural factors and potential issues around acceptability of bariatric surgery.
It is important to encourage and enable Indigenous women with PCOS to access services that are available and address potential barriers presented by cultural and traditional health practices. Work is currently underway to adapt, translate and implement the recommendations outlined here to Indigenous settings.
Development of an evidence-based guideline

Rationale and methods
Given its heterogeneous clinical features across the life span, PCOS is a condition that engages many health disciplines. The associated complications are serious yet are often largely preventable; however, there is a lack of awareness of PCOS among consumers and health professionals. It is essential that consumers and health professionals recognise the life-course implications of PCOS, identify the early signs and symptoms and work together to manage PCOS and prevent its complications -especially as the burden and cost of PCOS complications, including infertility, DM2, CVD and emotional wellbeing issues are significant.
Currently, there is limited consensus among different medical specialties as to the optimal management of PCOS in Australia. 7, 53 Diagnosis and treatment of PCOS can therefore differ depending on the health professional consulted (eg, general practitioner, endocrinologist or gynaecologist). 7 There are limited clinical guidelines and no evidence-based guidelines, either in Australia or internationally, for assessment or management of women with PCOS; rather, PCOS is briefly mentioned within guidelines for the management of obesity and DM2. 45, 54 Where international clinical guidelines for the assessment and management of women with PCOS exist, they are informed by expertise and, in some cases, evidence, but are not rigorously developed evidenced-based guidelines; they do not consider psychological issues; and they offer simplistic advice on lifestyle management of PCOS. There is no guidance on the assessment and management of PCOS among Indigenous women, nor any adaptation for the Australian context.
Overall, many areas of controversy remain in PCOS. Comprehensive evidence-based guidelines are warranted to optimise diagnosis, assessment and management. Accordingly, the Jean Hailes Foundation for Women's Health has facilitated the formation of an independent 
Infertility
• Lifestyle intervention (to optimise preconception health and fertility and reduce pregnancy and long-term complications)
• Advise on folate, smoking cessation and optimal weight and exercise before conception • Given age-related infertility, advise women to optimise family initiation • Infertility therapies may include clomiphene citrate, metformin, gonadotrophins, surgery and in-vitro fertilisation.
Cardiometabolic risk
• Lifestyle change: > 5% weight loss in those who are overweight reduces diabetes risk by approximately 50%-60% in high-risk groups 48 • Optimise cardiovascular risk factors • Consider metformin* (reduces the risk of diabetes by ~50% in adherent high-risk groups) 48 Adapted and reproduced with permission from Teede et al, 9 not generated directly from the evidence-based guidelines. Hirsutism therapy is summarised from existing hirsutism clinical practice guidelines.
44 * Metformin and the OCP are not currently approved for use to manage PCOS by many regulatory bodies. The OCP is indicated for contraception and metformin for diabetes. However, their use is supported by evidence and is recommended by international and national specialist societies. Supplement PCOS Australian Alliance, bringing together health professionals, researchers, consumers and policymakers to advance knowledge and quality of care in PCOS. The federal government has funded the PCOS Australian Alliance, under the auspices of the Jean Hailes Foundation, to produce national evidence-based guidelines. The full version of the guideline has been approved by the National Health and Medical Research Council (NHMRC) (for detail about obtaining NHMRC approval, please see the full guideline), is endorsed by the Royal Australian College of General Practitioners and is freely available at http:// www.managingpco s.org.au/pcos-evidence-basedguidelines.
8 This is a summary version of the full guideline. The Jean Hailes Foundation was funded to translate the guideline into practice, including freely available independent evidence-based information on PCOS for h e al t h p r o fe s s i o n a l s an d wo m en a t h t t p : / / www.managingpcos.org.au.
Scope
The purpose of the guideline is to integrate the best available evidence with clinical expertise and consumer preferences; to provide health professionals, consumers and policymakers with guidance on timely diagnosis, accurate assessment and optimal management of PCOS; and to promote consistency of care and prevention of complications in primary care and specialist settings.
The guideline is relevant to the assessment and management of reproductive-age adolescents and women with PCOS, including women with PCOS who are experiencing infertility. The guideline will apply in all health care settings and to a broad audience, including: community care practitioners; Indigenous health care workers; GPs; nurses; endocrinologists; obstetricians and gy nae c ol o gists; a ll ie d he a lth pro f e ssi o nal spsychologists, dietitians, exercise physiologists and physiotherapists; patients; community support groups (eg, the Polycystic Ovary Syndrome Association of Australia [POSAA]); the general public; students; and policymakers.
PCOS is a syndrome, and as such, no single diagnostic criterion is sufficient for diagnosis. The 2003 Rotterdam consensus workshop concluded that PCOS diagnosis requires at least two of: oligo-or anovulation, hyperandrogenism (clinical and/or biochemical) and polycystic ovaries on ultrasound (Figure 2 ).
14 The evidence-based guideline development groups and the Alliance agreed to endorse the Rotterdam diagnostic criteria for the guideline, while recognising there are current limitations of all definitions.
Methodology
Guidelines are intended to improve patient outcomes, promote standardised care, develop standards to assess the clinical practice of health care professionals, and promote research and translation into practice. Guidelines are developed by drawing from clinician judgement, patient preference and research evidence, and are intended to aid clinical judgement and patient preference, not to replace it (Figure 3 ). The ultimate decision about clinical management of an individual patient will always depend on the clinical circumstances, patient preferences, and the clinical judgement of the health care team. Although there are many types of guidelines, this NHMRC-approved evidence-based guideline followed a rigorous, systematic process of development, which is briefly outlined below and in detail in the full guideline. 8 An independent PCOS Australian Alliance was formed in 2008 after a national workshop facilitated by the Jean Hailes Foundation for Women's Health, which brought t o ge t h e r k ey l e a de rs f ro m t he re se a rc h a nd multidisciplinary clinical sectors, with consumers providing a driving force through the peak national support group, POSAA. The vision of the Alliance is to improve the lives of Australian women with PCOS through education, research and evidence-based health care. One of the priorities of the Alliance was to develop an evidence-based guideline for PCOS.
This guideline was developed as outlined in the NHMRC standards and procedures for externally developed guidelines. 55 The Alliance identified key clinical objectives for the guideline based on highest clinical priority, greatest knowledge gaps, factors identified by the Australian government (which funded the guideline), and the expertise of Alliance members. The identified key clinical priorities focused on care of women with PCOS to facilitate early diagnosis of PCOS; early detection and treatment of depression, anxiety and mood disorders; early detection and diagnosis of risk factors for prediabetes, DM2 and CVD; and early detection and treatment of fertility problems and prevention of pregnancy complications.
Multidisciplinary guideline development committees included a Project Board, PCOS Australia Alliance Strategic Advisory Group and four guideline development groups. Each guideline development group comprised a chair, professional group members with specific expertise Figure 3 . Evidence-based guidelines are intended as an aid to clinical judgement and patient preference, not to replace it in PCOS and the clinical area of interest (eg, psychologist in the emotional wellbeing guideline development group), a consumer representative from POSAA, evidence officers and, where possible, a representative to provide context for the Indigenous setting. Indigenous representation was present on the PCOS Australian Alliance Strategic Advisory Group, and the guideline development groups comprised clinicians with experience working with Indigenous communities.
These multidisciplinary groups determined and prioritised the clinical questions addressed in this guideline and developed the clinical practice and research recommendations from the evidence reviews. For more detail about the development and prioritisation of clinical questions, please see the full guideline.
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To facilitate this process using an evidence-based approach, the chairs of each guideline development group attended a 1-day workshop, facilitated by the Southern Health Centre for Clinical Effectiveness, where the methods of identifying, appraising and synthesising evidence; grading the strength of evidence and its suitability to support evidence-based recommendations; and the process of guideline development overall were described in detail.
Evidence reviews were conducted for each of the 22 identified clinical questions. Search strategies were developed according to a-priori selection criteria for each clinical question. Searches were limited to English language articles and there were no limits on year of publication. The literature was searched until November 2010. The following electronic databases were employed to identify relevant evidence: Australasian Medical Index, CINAHL, the Cochrane Library, the Cochrane Database of Systematic Reviews, DARE (Database of Abstracts of Reviews of Effects), the Cochrane Central Register of Controlled Trials, the Cochrane Database of Methodology Reviews, the Cochrane Methodology Register, Health Technology Assessment Database, the United Kingdom National Health Service Economic Evaluation Database, E M BA S E , E B M R , M E D L I N E a n d P s yc I N F O. Bibliographies of relevant studies identified by the search strategy and relevant reviews/meta-analyses were also searched. Included studies were classified according to the NHMRC levels of evidence 56 and appraised using a-priori criteria according to study design, using a descriptive component approach to assign a risk of bias rating. 57 In accordance with the selection criteria, data were extracted from included studies using a specially developed data extraction form, 57 and meta-analyses were performed where appropriate. The guideline development groups were able to develop guideline recommendations from these evidence reviews. The evidence reviews for each question can be found in the supporting document to the full guideline: Evidence report: evidence based guidelines for assessment and management of PCOS, available at http:// www.managingpco s.org.au/pcos-evidence-basedguidelines.
The guideline contains 38 recommendations, each of which is assigned a grade. In developing the guideline recommendations, the guideline development groups placed emphasis on accurate assessment and management of PCOS. The recommendations in this guideline are strengthened by the use of rigorous methodology for evidence review and guideline development, including use of: study designs least susceptible to bias; a-priori criteria for inclusion and appraisal of studies; extraction of study data; and meta-analysis where appropriate. The recommendations were formulated using a considered judgement process that took into account the amount and quality of available evidence as well as its generalisability and applicability to current practice in Australia.
Each evidence-based recommendation was given an overall grading from A to D, according to the NHMRC grades of recommendations for guideline developers (Table 1) . 56 Evidence grading is provided primarily to inform users about the strength of the evidence underpinning each recommendation. Where there was insufficient high-quality evidence in specific patient groups, lower-quality evidence or data from other patient groups, and where there was consensus among the guideline development group, combined with clinician and patient preferences, clinical consensus recommendations were developed. Clinical practice points have also been included, where important issues (such as safety, side effects or risks) arose from discussion of evidence-based or clinical consensus recommendations. Further points of re l e v a n c e t o t h e c l i n i c a l i m p l e m e n t a t i o n o f recommendations were made in "implications of the recommendations" sections, including consideration of resource implications.
The words "should", "could" and "should not" do not directly reflect the grade or classification allocated to a recommendation, and are independent descriptors intended to reflect the judgement of the multidisciplinary guideline development group about the practical application of the recommendation, balancing benefits and harms. Where the word "should" is used in the recommendations, the guideline development group judged that the benefits of the recommendation (whether evidence-based or clinical consensus) clearly exceed the harms, and that the recommendation can be trusted to guide practice. Where the word "could" is used, either the quality of evidence was underpowered, or the available studies demonstrated little clear advantage of one approach over another, or the balance of benefits to harm was unclear. Where the words "should not" are used, there is either a lack of appropriate evidence, or the harms outweigh the benefits.
In formulating the recommendations for this guideline, the guideline development groups recognised and took into account several factors and limitations pertaining to the available evidence. For many aspects of PCOS, there is 55 and accordingly, the guideline was approved by the NHMRC in July 2011. In approving the full version of the guideline, the NHMRC is satisfied that it is based on the systematic identification and synthesis of the best available scientific evidence and makes clear recommendations for health professionals practising in an Australian health care setting.
This guideline does not seek to provide full safety and usage information on pharmacological and surgical interventions. The pharmacological and surgical interventions recommended in the guideline should not be applied without consideration of the patient's clinical profile and personal preferences. It is recommended that the reader consults the Therapeutic Guidelines (http:// www.tg.com.au) and the National Prescribing Service (http://www.nps.org.au) for detailed prescribing information, including indications, drug dosages, methods and routes of administration, contraindications, supervision and monitoring, product characteristics, and adverse effects.
It is intended that this evidence-based guideline summary be used alongside the full guideline. 8 The guideline should be considered according to the limitations outlined within, and used in conjunction with clinical judgement and patient preference. For a detailed description of the methodology used to develop the guideline, please see the full guideline. 8 Translation of the guideline, including the production and dissemination of guideline-associated tools and resources, is the responsibility of the Jean Hailes Foundation for Women's Health as a national not-forprofit women's health organisation funded by the federal government. The PCOS Alliance and POSAA provided significant contribution to these resource developments.
Summary of the evidence-based guideline for PCOS
The recommendations in the guideline are summarised in the algorithms and are outlined in the following sections.
Summary of the evidence-based guideline Section 1. Challenges in diagnostic assessment of PCOS (Algorithm 1) PCOS is diagnosed based on at least two of: oligo-or anovulation, hyperandrogenism (clinical and/or biochemical) and polycystic ovaries on ultrasound after exclusion (where relevant) of other conditions such as thyroid dysfunction, congenital adrenal hyperplasia, hyperprolactinaemia, androgen-secreting tumours and Cushing syndrome (Figure 2 ).
14 Diagnosis of PCOS is challenging, as the presenting symptoms and signs are heterogeneous, depending on populations studied, degree of obesity and life stage of the women affected; indeed, clinical features can vary over time within an individual woman. The key identified challenges in diagnosis prioritised in the guideline included assessment of biochemical hyperandrogenism, and diagnosis of ovulatory dysfunction, polycystic ovaries and PCOS in adolescents.
Clinical question. In women with suspected PCOS, what is the most effective measure to diagnose PCOS-related hyperandrogenism?
Recommendations
Clinical consensus recommendation 1.1a Late-onset congenital adrenal hyperplasia, although rare, needs to be considered before the diagnosis of polycystic ovary syndrome is confirmed. In more severe clinical cases of hyperandrogenism, 21-hydroxylase deficiency, the most common form of congenital adrenal hyperplasia, can be excluded by measuring serum 17-hydroxyprogesterone in the follicular phase to explore this diagnosis.
Evidence-based recommendation 1.1b Calculated bioavailable testosterone, calculated free testosterone or free androgen index should be first line investigation for biochemical determination of hyperandrogenism in polycystic ovary syndrome.
The addition of androstenedione and dehydroepiandrosterone sulfate could be second line investigation for biochemical determination of hyperandrogenism in polycystic ovary syndrome. -level C Clinical practice points 1.1c It is difficult to assess androgen status in women on the oral contraceptive pill as effects include oestrogen mediated increases in sex hormone-binding globulin and reduction in androgens.
Where the oral contraceptive pill has already been commenced, it should be withdrawn for at least three months before appropriate hormonal assessments for diagnosis of polycystic ovary syndrome are undertaken. Contraception should be otherwise managed during this time.
1.1d If androgen levels are markedly above laboratory reference ranges, secondary causes may be considered. Mild elevations of androstenedione may be seen in polycystic ovary syndrome, whereas marked elevations are more indicative of non-classical adrenal hyperplasia.
Reference ranges for different methods and different laboratories vary widely and clinical decisions should be guided by the reference ranges of the laboratory used.
Context. Hyperandrogenism is a well established contributor to PCOS aetiology, detected in around 60%-80% of cases, yet it is challenging to diagnose. It includes clinical and biochemical hyperandrogenism. When determining biochemical hyperandrogenism, accurate diagnosis is hampered by a lack of ideal methods of measurement. Testosterone assays are generally designed for use in males, with poor accuracy noted at the lower androgen levels characteristic of females. In this setting, calculated measures of free androgens are preferred for diagnosis of PCOS. To improve accuracy, testosterone should ideally be measured in the morning in the follicular phase (in cycling women). For those with irregular cycles, measurement of FSH, luteinising hormone, oestradiol and progesterone may be helpful to assess the phase of cycle and thus interpretation of androgen levels. The optimal methodology for testosterone measurement on which to base calculated measurements is unclear; however, Davison and colleagues have described a highly sensitive direct manual radioimmunoassay in the Australian setting that more accurately measures total testosterone than other assays, and that provides reference values for androgens by age. 58 Calculated measures of androgen status in PCOS include calculated bioavailable testosterone and calculated free testosterone, which can be used interchangeably with calculated free testosterone, the most commonly measured marker, using the formula of Vermeuelen and colleagues. 59 The free androgen index (FAI) is also a widely used measure of androgens among women, calculated based on testosterone and sex hormone-binding globulin (SHBG) levels. Other androgens, including androstenedione and dehydroepiandrosterone sulfate (DHEAS), can also be measured. These can be mildly elevated in PCOS; however, these additional androgen tests are primarily indicated in women with rapidly progressive virilisation or more severe clinical hyperandrogenism. DHEAS elevation is more marked among patients with androgen-secreting adrenal tumours, and androstenedione levels are especially elevated among patients with non-classical congenital adrenal hyperplasia. Given the controversy, methodological challenges and variety of different options for the biochemical measurement of androgens, there is uncertainty and inconsistency in clinical practice; hence, this was prioritised during the process of guideline development. Evidence informing the recommendations. Three diagnostic studies (NHMRC level III-2) with low, moderate and high risk of bias compared the diagnostic accuracy of different reproductive hormone markers in serum to detect PCOS. [60] [61] [62] For diagnosis of PCOS, calculated bioavailable and free testosterone were better than androstenedione, SHBG and total testosterone levels, and the FAI was better than androstenedione and SHBG levels. 61 The remaining two studies provided insufficient Supplement lower-quality evidence to support any differences between total testosterone, SHBG and androstenedione levels with respect to their value in PCOS diagnosis.
60,62
Implications of the recommendations. Because different laboratories currently use different methodologies, specific cut-off values to determine hyperandrogenism cannot be recommended and should be based on appropriate laboratory-specific reference intervals. Current practice in androgen measurement in PCOS is unclear, so the recommendation may require changes in usual care. There may be resource implications, as the cost of a calculated testosterone test involves measurement of testosterone and SHBG levels, and this test is more expensive than a testosterone level alone. However, more targeted first-line androgen testing may also reduce costs. The field of androgen testing is constantly changing and is likely to keep changing in the future. New automated technology (liquid chromatography mass spectrometry) is currently being introduced in many laboratories. This will need to be considered when implementing these recommendations. Clinical practice point 1.2b If oral contraceptive pill therapy is being considered or has commenced in adolescents (< 18 years), the following are recommended:
• After twelve months of irregular cycles (> 35 or < 21 days) after onset of menarche, polycystic ovary syndrome should be considered before commencement of the oral contraceptive pill.
• Where the oral contraceptive pill has already been commenced, when girls are not sexually active, if biochemical hyperandrogenism is needed for the diagnosis of polycystic ovary syndrome, the oral contraceptive pill could be withdrawn for three months to facilitate appropriate hormonal assessments.
Withdrawal of the oral contraceptive pill may facilitate assessment and early diagnosis of polycystic ovary syndrome as diagnosis can have important implications including optimisation of healthy lifestyle, regular metabolic screening and proactive fertility planning, with consideration of planning for conception at an earlier age.
However, the risk of unplanned pregnancy needs to be considered and weighed up against potential benefits of early diagnosis. Contraception may still need to be otherwise managed during this time.
Context. Physiologically, during the first ye ar postmenarche, hormonal responses do not match adult patterns. During the second year, hormonal profiles are similar to control-group adult women during both phases of the menstrual cycle, although progesterone levels remain lower. 63 The average adult menstrual cycle is 28 days, with a normal cycle range of 24 to 35 days. 64 However, during the first few years postmenarche, cycles vary considerably. [64] [65] [66] In the first postmenarcheal year, around half of cycles are anovulatory. Nonetheless, 80% of cycles occur within a predictable range of 21 to 45 days. [65] [66] [67] [68] By the third postmenarcheal year, 95% of cycles fall into this range; as such, the minority without regular cycles after 2 years postmenarche should be investigated for PCOS.
Another clinical consideration when determining whether cycle irregularity is normal or abnormal in adolescents is that the onset of regular ovulatory cycles is related to age at menarche. 69 Of girls who begin menses at before 12 years of age, between 12 and 13 years, and after 13 years of age, 50% of cycles are ovulatory by 1 year, 3 years, and 4.5 years, respectively. 69 Weight and exercise influence the menstrual cycle of women in many ways and should always be evaluated when assessing a women with menstrual disturbance. As it remains unclear at what stage irregular cycles in adolescents reflect immaturity of the reproductive system or possible PCOS, this question was prioritised during the process of guideline development. Evidence informing the recommendations. We did not identify any evidence from our PCOS patient population to answer the question; therefore, a clinical consensus recommendation has been made, informed by the natural history of menstrual cycles and ovulation in adolescents (aged < 18 years). Implications of the recommendations. Irregular cycles (> 35 or < 21 days) that continue for more than 2 years after the onset of menarche are likely to reflect oligo-or anovulation. Consideration should be given to age of menarche. Current practice is unclear. It is likely that current practice involves prescription of the oral contraceptive pill without diagnosis of PCOS in adolescents with irregular cycles. This recommendation may increase referral for diagnostic testing and specialist care; however, the benefits of early diagnosis and prevention of associated complications and infertility are likely to result in significant health and cost benefits. Focus on lifestyle mana geme nt, rather than medical management, may also be increased.
Clinical question.
In adolescents, what are the most effective criteria to diagnose polycystic ovaries on ultrasound?
Recommendations
Clinical consensus recommendation 1.3a Given the apparent lack of specificity of polycystic ovaries on ultrasound in adolescents, generally, ultrasound should not be recommended first line in this age group for diagnosis of polycystic ovary syndrome pending further research. If pelvic ultrasounds are to be ordered in adolescents, the results should be interpreted with caution. Clinical practice point 1.3b Vaginal ultrasound is not appropriate in adolescents who have not been sexually active.
Context. Between the ages of 2 and 9 years, the size and morphology of the ovaries are relatively stable, with the volume of each ovary being less than 2 cm 3 ; however, from around 9 years of age onward, the ovaries undergo progressive increases in size. 70 The number of large antral follicles and ovarian size reaches its maximum around the time of menarche 71, 72 and many girls with regular menstrual patterns may have polycystic ovaries. 71 Recently, on community-based screening, up to 68% of 19-21-yearold Danish women were shown to have polycystic ovaries according to the Rotterdam criteria. 16 As follicle counts are high at a younger age, this needs to be considered to avoid overdiagnosis of PCOS. 16 It seems unlikely that the adult criteria for diagnosing PCOS according to polycystic ovaries (presence of 12 or more follicles in each ovary measuring 2-9 mm in diameter, and/or increased ovarian volume [> 10 mL] 14 ) are directly applicable to adolescents. There is continuing discussion as to the quantitative characteristics of a polycystic ovary given increasing resolution of ultrasound. The appropriateness of vaginal ultrasound in adolescents who may not yet have been sexually active has also been questioned. Given the controversy in this area, it was prioritised during the process of guideline development. Evidence informing the recommendations. One level III-3 case-control study with moderate risk of bias 73 was identified by our search to answer the question, and was deemed insufficient evidence on which to base a recommendation. Therefore, a clinical consensus recommendation was made, based on the clinical expertise of the multidisciplinary guideline development group, informed by observational data in this patient population. Implications of the recommendations. There is a high prevalence of polycystic ovaries among adolescents, and normal reference ranges for this age group have not been developed or validated. Hence, pelvic ultrasound should be used and interpreted with caution in this age group. Original NIH criteria based on ovulatory disturbance and hyperandrogenism may be the optimal way to diagnose PCOS in adolescents. Although current practice is unclear, it is anticipated that the recommendations may result in less use of ultrasound in PCOS diagnosis in adolescents.
Research recommendation
Further methodologically rigorous trials are important to determine:
1 Natural history of menstrual cycles in PCOS compared to non-PCOS adolescents 2 Age-appropriate normal ranges for sonographic features of polycystic ovaries and for clinical and biochemical features of PCOS in adolescents (< 18 years) Successful collaboration also relies on adequate systems and organisational supports. 75 Although seemingly intuitive, a recent Cochrane review revealed only poorquality studies, 76 highlighting a key research gap and the need for evaluation strategies in development and implementation of interdisciplinary models of care. For these reasons, this area was prioritised during the process of guideline development. Evidence informing the recommendations. We did not identify PCOS-specific evidence to answer the question, so a clinical consensus recommendation was made based on clinical expertise, informed by the literature in other chronic disease areas. Implications of the recommendations. Current PCOS management involves one or more health professionals managing individual components of the syndrome ( Figure  4 ). As interdisciplinary care emphasises shared decision making, mutual respect between all collaborating members, interactive communication and active patient empowerment, changes to current management and change in the cultural mindset and philosophy of clinicians may be required. Current Australian funding arrangements may hinder community-based interdisciplinary care. Medicare funding for allied health professionals is capped, and although care plans facilitate chronic PCOS care, these may be underutilised and may benefit from adaptation for complex chronic health problems like PCOS. Clinical consensus recommendation -cardiovascular risk 3.1a All women with polycystic ovary syndrome should be assessed for cardiovascular disease risk by assessing individual cardiovascular disease risk factors. If screening in women with polycystic ovary syndrome shows that any of the following cardiovascular disease risk factors are present, these women should be considered at increased relative risk of cardiovascular disease (obesity, cigarette smoking, dyslipidemia, hypertension, impaired glucose tolerance, lack of physical activity) and those with metabolic syndrome and/or type 2 diabetes, at even greater risk.
Clinical consensus recommendation -weight and cigarette smoking 3.1b All women with polycystic ovary syndrome should be assessed for excess weight at every visit. In assessing women with polycystic ovary syndrome < 18 years, age appropriate and gender appropriate body mass index should be calculated at every visit. All women with polycystic ovary syndrome should be assessed for cigarette smoking. Clinical practice point 3.1e In women with polycystic ovary syndrome, a lipid profile should include:
• Total cholesterol -total cholesterol should be < 4 mmol/L
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• Low-density lipoprotein cholesterol (LDL-C) -in women without additional cardiovascular disease risk factors, LDL-C levels should be < 3.4 mmol/L. 78 In women with metabolic syndrome or type 2 diabetes, LDL-C levels should be < 1. Context. Women with PCOS often have increased cardiovascular risk factors (hyperinsulinaemia, dyslipidaemia, hypertension) and increased prevalence of metabolic syndrome 81 ( Figure 5 ). Dyslipidaemia in PCOS is underpinned by overproduction of triglyceride-rich lipoproteins and increased catabolism of high-density lipoproteins 82 in the setting of IR and excess visceral and hepatic fat. 82 In PCOS, other novel CVD risk factors, premature cardiovascular dysfunction and subclinical CVD 29, 30, 83 have been noted and are related to IR and obesity. [84] [85] [86] [87] [88] [89] This evidence, along with high diabetes risk, suggests an increased relative risk of CVD in PCOS.
Two large epidemiological studies have reported increased prevalence of CVD among women with anovulation; 90, 91 however, poor-quality long-term PCOS studies have not shown increased CVD. 89, 92 In contrast, Shaw and colleagues examined a subset of postmen-pausal women from the Women's Ischemia Syndrome Evaluation study who had displayed clinical features consistent with PCOS and confirmed increased cardiovascular events and deaths. CVD is the biggest killer of Australian women and approximately 80% is preventable through lifestyle change. The public health impact of early identification and targeted prevention in high-risk, young, reproductiveage women with PCOS is likely to be very significant; [93] [94] [95] [96] however, the best method for assessing cardiovascular risk in women with PCOS remains unclear and was prioritised during the process of guideline development. Evidence informing the recommendations. We did not identify high-quality PCOS-specific evidence to answer the question, hence a clinical consensus recommendation was made based on clinical expertise, an international position statement on CVD risk assessment in PCOS 78 98 • Impaired fasting glucose -fasting plasma glucose:
6.1-6.9 mmol/L
• Impaired glucose tolerance -2-hour glucose level:
• Type 2 diabetes -fasting plasma glucose: у 7.0 mmol/L; or 2-hour oral glucose tolerance test: у 11.1 mmol/L.
Ideally, 150 grams of carbohydrate per day should be consumed for 3 days before, and women should then fast for 8 hours immediately before the oral glucose tolerance test, since low carbohydrate intake may lead to false positive glucose tolerance tests.
Context. IR is a key aetiological feature in PCOS, worsening the reproductive and metabolic features, type 2 diabetes and CVD risk. 30, 99, 100 IR is present in around 50%-80% of women with PCOS, independent of obesity, 101 and is further exacerbated by excess weight. 20 11,103 -independent of, but exacerbated by, obesity. Earlier-onset hyperglycaemia and rapid progression to DM2 is also reported in PCOS. 104, 105 In this context, PCOS is listed by the International Diabetes Federation as a non-modifiable risk factor for DM2. 106 Furthermore, lifestyle therapy has been shown to prevent or delay progression to DM2.
Previous studies have noted that fasting blood glucose level alone appears to lack sensitivity in screening for prediabetes or DM2 in PCOS, with national and international groups recommending screening all women with PCOS with an OGTT. 78, 107 It is important to note that assessment of IR or measurement of serum insulin levels has no current role in clinically assessing for risk of DM2. Although the high risk of DM2 is recognised in PCOS and screening is important to facilitate effective lifestyle therapy to prevent DM2, which patients to target, how to test and at what frequency remain unclear and were prioritised during the process of guideline development. Evidence informing the recommendations. We identified one low-quality systematic review (level I) with high risk of bias; 108 however, this was deemed insufficient evidence on which to base the recommendation. A clinical consensus recommendation was made based on the previous national and international publications suggesting screening all women with PCOS with an OGTT, 78,107 on the systematic review, on a recent an international position statement on CVD risk assessment in PCOS 78 and on national guidelines for case detection and diagnosis of DM2.
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Implications of the recommendations. The significantly increased risk of DM2 in PCOS represents a major health and economic burden. The recommendation to screen all women with PCOS and to use an OGTT will result in Figure 6 . Anxiety and depression, poor body image, eating disorders and psychosexual dysfunction are all likely to affect quality of life in polycystic ovary syndrome earlier detection of prediabetes and DM2, and will present opportunities for prevention of DM2 and its complications, through effective lifestyle intervention, as outlined below. Resource implications include increased screening tests, counterbalanced by earlier detection and potential for prevention. However, it is acknowledged that OGTTs increase inconvenience for patients, which may affect compliance. Other anticipated changes to diagnosis of diabetes may impact on these recommendations including the role of glycated haemoglobin, which is currently under review at national and international levels.
Research recommendation
Further methodologically rigorous trials in women with polycystic ovary syndrome are important to determine: • Kessler Psychological Distress Scale 10 (K10)
• Depression Anxiety Stress Scale (DASS21)
• Patient Health Questionnaire (PHQ9)
• Generalized Anxiety Disorder 7-item scale (GAD7).
Context. Prevalence of depression among women with PCOS is higher (28%-64%) 5,109,110 than in the general population (7.1%-8.0%). 111, 112 Prevalence of anxiety among women with PCOS ranges from 34% 113 to 57%; 5 again, higher than in the general population (18%). 111 Women with PCOS are also likely to experience more severe anxiety and depression. 5,10 Contributing factors remain controversial, but include clinical symptoms of PCOS, excess weight, and the chronic and complex nature of PCOS. The higher prevalence and severity of mood disorders in PCOS is likely to affect self-efficacy and ability to adhere to lifestyle management in PCOS. Mood also adversely affects overall QoL. Assessment of depression and/or anxiety for women with PCOS is important, as recognition and treatment improves emotional wellbeing and QoL (Figure 6 ) and is likely to improve effectiveness of lifestyle intervention in PCOS. Given that recognition of depression and anxiety remains poor in PCOS, screening and assessment was prioritised during the process of guideline development. Evidence informing the recommendations. We did not identify any PCOS-specific evidence to answer the question, so a clinical consensus recommendation was made based on key relevant sources of evidence-based information for mood disorders in the general population c o m bi n e d w it h t h e c li n i c a l e x p e rt i se o f th e multidisciplinary guideline development group. Several other relevant national and international guidelines were also used to inform the recommendations. 36, 38, [41] [42] [43] Implications of the recommendations. It is the responsibility of all health professionals to understand the impact of PCOS on psychological health and to screen, assess and manage these disorders. However, it is not usual practice to screen women with PCOS for depression and/or anxiety. Screening may uncover undiagnosed mood disorders with resource implications including increasing consultation duration. This can be attenuated by the use of the freely available recommended tools and the guidelinedeveloped brief PCOS emotional wellbeing general screening tool (see Appendix V in the full guideline).
8 If depression and or anxiety are detected, intervention may require referral to other health practitioners or the use of other avenues (eg, an Australian GP Mental Health Care Plan), to optimise access to relevant mental health professionals. Access to appropriately trained health professionals will be required. Context. Body image is complex and is influenced by many factors. In this guideline, body image is defined as the way a person feels about, thinks of and views their body, including their appearance. Body image includes attitudes to physical appearance, understanding of health, physical fitness and body size, the mental picture that individuals form of their body, values and self-esteem (Figure 7 ).
Supplement
Physical factors affecting appearance (excess weight and hirsutism), psychological (self-esteem) and sociocultural factors can influence body image. Body image is generally poor in women, yet negative body image is more prevalent among women with PCOS and affects thoughts and feelings about health and appearance, QoL, mood and physical fitness. 114, 115 Negative body image also predicts depression and anxiety. 116, 117 Given the impact of negative body image on mood and QoL, body image in women with PCOS should be considered. If identified, addressing negative body image and associated mood disorders is important for improving emotional wellbeing and QoL in PCOS (Figure 6 ). However, body image is often not considered in PCOS; hence, this area was prioritised during the process of guideline development. Evidence informing the recommendations. We did not identify any PCOS-specific evidence to answer the question, so a clinical consensus recommendation has been made based on key relevant sources of evidencebased information for the general population and the clinical expertise of the multidisciplinary guideline development group.
37,39
Implications of the recommendations. It is not usual practice to screen women with PCOS for negative body image. However, its detection provides an opportunity to address psychological aspects, such as self-esteem and self-acceptance, and the physical aspects, such as hirsutism and excess weight. Screening may increase consultation lengths; however, this can be reduced by the emotional wellbeing screening tool and other tools recommended here (see Appendices V and VI in the full guideline).
8 Intervention may require referral to other health practitioners. Where needed, access to appropriately trained and experienced health professionals is required. A shift in cultural mindset may be required to ensure the clinical impact of negative body image is understood and addressed.
Clinical question. In women with PCOS, what is the most effective tool/method to assess disordered eating?
Recommendations
Clinical consensus recommendation 4.3a Disordered eating, including eating disorders, should be considered in women with polycystic ovary syndrome.
If Context. Australian research suggests that prevalence of diagnosable eating disorders is increasing. 118 Disordered eating refers to eating-and weight-related symptoms and can include behavioural (eg, bingeing, excessive restriction), cognitive (eg, excessive dietary restraint, negative body image) and emotional factors (Figure 7) . The consequences of eating disorders encompass medical, psychological, social and occupational difficulties 118, 119 and are associated with an increased prevalence of mood disorders. 119 Prevalence data on eating disorders in PCOS is limited, with links between PCOS and bulimia nervosa 120, 121 and abnormal eating behaviour. 120, 122, 123 The prevalence of any eating disorder has been reported at 21% in PCOS, 124 with high rates of associated mood disorders; 62% had major depression and 41% anxiety disorders. Women with PCOS have higher prevalence of risk factors for eating disorders, including excess weight, depression, anxiety, low selfesteem and poor body image. 119 There may also be more motivation for weight loss and prescribed and selfimposed dietary restriction in PCOS.
Available research suggests that fewer than half of patients with clinically significant eating disorders are identified in primary care, potentially related to patient ambivalence, secrecy and shame or health practitioner knowledge, attitudes and skills. Health practitioners are well placed to identify these problems, with management potentially improving physical and psychological functioning and QoL in PCOS ( Figure 6) ; hence, this area was prioritised during the process of guideline development. Evidence informing the recommendations. We did not identify any evidence in women with PCOS to answer the question; therefore, a clinical consensus recommendation was made based on key relevant sources of evidence-based information for the general population and the clinical Figure 7 . Continuum of disordered eating and body image expertise of the multidisciplinary guideline development group. Implications of the recommendations. It is not usual practice to screen women with PCOS for disordered eating. It is likely that improved screening practices will increase identification of disordered eating/eating disorders, whereby effective treatment is available. [125] [126] [127] [128] Resource implications include potentially increased consultation lengths, which the emotional wellbeing general screening tool and other tools recommended here may assist with (see Appendices V and VI in the full guideline). 8 Increased detection of disordered eating will result in increased referrals to other health professionals, and access to appropriately trained and experienced health professionals will be required. A shift in cultural mindset may be required to ensure the clinical impact of eating disorders is understood and addressed. Clinical practice point 4.4b To screen for psychosexual dysfunction, the following questions could be asked: 1 During the last few months, have you often been bothered by problems with your sex life such as reduced satisfaction, diminished desire, pain, or any other problems? 2 Do you feel that polycystic ovary syndrome affects your sex life? 3 (If relevant) Do sexual problems affect your current relationship and/or have sexual problems affected your past relationships? If a woman with polycystic ovary syndrome answers yes to any of the above questions or where sexual function is a concern, the practitioner should assess this through more detailed clinical interview, and in particular screen for depression and/or anxiety if not already done (see 4.1) and negative body image (see 4.2) or refer to a more appropriately qualified health practitioner.
Specific validated scales could be used as outcome measures at baseline to monitor progress over time. The choice of scale should be selected by the discretion of the clinician, based on the specific sexual problem, accessibility and expertise of the practitioner.
Context. Psychosexual dysfunction refers to sexual problems or difficulties that have a psychological origin based in cognitions and/or emotions such as depression, low self-esteem and negative body image. 129 It appears that women with PCOS suffer from greater psychosexual dysfunction than women in the general population with correlations between PCOS and reduced QoL, sexual satisfaction and feminine identity. [130] [131] [132] Physical PCOS symptoms such as hirsutism, obesity, menstrual irregularity and infertility may cause loss of feminine identity that can affect sexuality. 130, 132, 133 Women with PCOS also report less sexual satisfaction and lower sexual self-worth than women without PCOS, which adversely affects their relationships. 134 Clinicians should be aware of potential psychosexual dysfunction in PCOS and screening and assessment should be considered. Evidence informing the recommendations. We did not identify any PCOS-specific evidence to answer the question; therefore, a clinical consensus recommendation was made based on key relevant sources of evidence-based information for the general population and the clinical expertise of the multidisciplinary guideline development group. Implications of the recommendations. Screening and assessment for psychosexual dysfunction should be considered in sexually active women in order to facilitate appropriate intervention aiming to optimise sexual function, limit the social impact of PCOS and improve QoL (Figure 6 ). It is not usual practice to screen and assess women with PCOS for psychosexual dysfunction and screening may detect undiagnosed cases. Screening may have resource implications such as an impact on length of consultation, and intervention may require referral to other specialist health professionals.
Research recommendation
Further methodologically rigorous trials in women with polycystic ovary syndrome are important to determine the most effective tool to assess and optimal approaches to manage: Context. Women with PCOS appear to be heavier than women without PCOS, and to gain more weight longitudinally. 135, 136 Excess weight increases the risk of developing PCOS and increases the clinical severity of the condition by exacerbating both androgen and insulin levels. 93, 102 Indeed, excess weight increases the severity of reproductive, 20, 21 psychological and metabolic features in PCOS. 84, 85 Along with the recognised challenges of managing established excess weight, there is a clear argument for prevention of weight gain.
Weight loss also appears to offer considerable benefits to most women with PCOS who are already overweight. There is a large number of small, uncontrolled trials demonstrating that weight loss achieved through lifestyle management decreases abdominal fat, hyperandrogenism and IR and improves lipid profiles, ovulation, menstrual cyclicity, fertility, risk factors for DM2 and CVD and psychological health in women with PCOS who are overweight. [137] [138] [139] [140] Furthermore, among women with PCOS and excess weight, a reduction of as little as 5% of total body weight has been shown to improve outcomes. Hence, lifestyle management is useful for targeting weight loss and prevention of weight gain, and is first-line treatment for a large proportion of women with PCOS. Lifestyle management may also improve PCOS independent of weight loss, with exercise intervention improving metabolic risk factors associated with PCOS, including hypertension, IR and elevated blood glucose levels, even when no weight loss occurs. [160] [161] [162] However, it is difficult to be certain about the effectiveness of lifestyle interventions in women with PCOS, because available information is based on small uncontrolled trials that address different outcomes in different subgroups of women, and specific recommendations remain unclear. Hence, this area was prioritised during guideline development. Evidence informing the recommendations. One highquality systematic review (level I) with a low risk of bias appraised six randomised controlled trials (RCTs) (low to moderate quality and moderate to high risk of bias) and found that lifestyle intervention (diet, exercise and/or behaviour) outperformed minimal treatment for total testosterone (P = 0.004), hirsutism by Ferriman-Gallwey score (P = 0.04), weight (P < 0.001), waist circumference (P = 0.006), waist-hip ratio (P = 0.02), fasting insulin (P = 0.002) and OGTT insulin (P < 0.001), and percent weight change (P < 0.001). There was no difference between the two interventions for BMI, FAI, SHBG, blood glucose levels or lipid levels. QoL, patient satisfaction and acne were not reported. 163 Due to the inconsistencies and methodological weaknesses of included studies, caution is recommended when interpreting the combined metaanalyses and results of the systematic review. None of the studies addressed fertility outcomes. Implications of the recommendations. It is likely that the recommendation will reduce variation in practice and ensure lifestyle advice is prescribed to all women with PCOS, targeting prevention of weight gain and promoting weight loss, where appropriate. The recommendation may increase consultation times, use of care plans, and referral to allied health professionals. This may increase health care costs, but long-term benefits of lifestyle change should reduce the health and economic burden of PCOS. Barriers to implementation include engagement of health practitioners, access to allied health professionals and financial constraints. Insufficient consultation time allocated by health professionals may also be a barrier, and a shift in cultural mindset may be required to focus on lifestyle interventions, especially around prevention of weight gain. In high-risk populations, where cardiometabolic and DM2 risk is increased, the impact of weight gain appears to be more significant than in Caucasian populations, and this needs to be considered when assessing and managing PCOS.
Further methodologically rigorous trials in women with polycystic ovary syndrome are important to address:
• The extent of the benefits of lifestyle management compared to no or minimal therapy for all clinically relevant outcomes 164 Structured exercise training (SET) was better than diet for menses frequency (P = 0.04) and ovulation rate (P = 0.03). There was no difference between interventions for anthropometric, metabolic, non-fertility or QoL outcomes; however, subgroup analysis in ovulatory women revealed that SET was better than diet for fasting insulin (P < 0.05), fasting glucose-to-insulin ratio (P < 0.05), homeostasis model of assessment of IR (P < 0.05), SHBG (P < 0.05) and FAI (P < 0.05). Diet was better than SET for weight (P < 0.05) and BMI (P < 0.05). This evidence is generalisable to PCOS, particularly to women who have BMI у 33 kg/m 2 . 164 There may be limitations to generalising the findings of this study, which was conducted in Italy, to other ethnic groups. The evidence is limited to the particular exercise (bicycling) and diet (high-protein, low-carbohydrate) interventions used in the study. Implications of the recommendations. Successful lifestyle components, including diet and exercise, separately and in combination, have significant health benefits and should be combined. It is acknowledged that there may be changes to usual care and the way care is organised, and there are potentially greater barriers to integration of exercise in lifestyle interventions for young women. However, it is expected that the cost of lifestyle interventions will be less than the cost of pharmacological intervention.
Clinical question. In women with PCOS, are diet interventions (compared to no diet or different diets) effective for improving weight loss, metabolic, fertility, and emotional wellbeing outcomes?
Recommendations
Evidence-based recommendations 5.3a Weight loss should be targeted in all women with polycystic ovary syndrome and body mass index у 25 kg/m 2 (overweight) through reducing dietary energy (caloric) intake in the setting of healthy food choices, irrespective of diet composition. Context. An area of increasing focus in PCOS is the macronutrient composition of the dietary component of a lifestyle intervention. Specific approaches including modifying carbohydrate, protein or fat are proposed to have favourable hormonal or metabolic effects or be more sustainable. Systematic reviews in the general population report similar or less weight loss and compliance with lowfat diets, 165, 166 and a large RCT reported similar changes in weight for a range of reduced energy diets with different macronutrient content over 2 years.
167 Caloric (energy) restriction per se, rather than changes in macronutrient composition, appears most effective for weight loss and clinical benefits, and with limited research in this area in PCOS this question was prioritised during guideline development. Evidence informing the recommendations. Six articles reporting five RCTs of moderate 139, 145, 156, 168 to high risk of bias 169, 170 were identified to answer this question. The studies compared macronutrient dietary compositions, including low-carbohydrate, low glycaemic-index, monounsaturated fatty acid-enriched, conventional healthy diet, high-protein, carbohydrate-counting, or fatcounting dietary approaches. There was no difference for most anthropometric, metabolic, fertility, non-fertility, QoL and emotional wellbeing outcomes. Regardless of diet composition, a diet aimed at reducing weight yielded benefits in PCOS. The evidence is generalisable to PCOS, particularly to women over 30 years of age and who have BMI у 30 kg/m 2 . However, most studies recruited Caucasian women and may not be generalisable to other ethnic groups. Implications of the recommendations. Healthy food choices (Figure 8 ) in energy-reduced diets, irrespective of composition, are recommended in overweight and obese women (BMI у 25 kg/m 2 ) with PCOS for weight loss, and in lean women (BMI < 25 kg/m 2 ) with PCOS for prevention of weight gain. Most practitioners do not recommend specific dietary composition, so this may not change usual care. However, consumer-targeted marketing claims benefits for specific macronutrient composition in PCOS, so greater education to ensure consumers understand the principles of evidence-based dietary approaches is important. The guideline development group is not aware of resource implications, changes to the way care is Supplement organised, or barriers to implementation of these recommendations.
Research recommendation
Further methodologically rigorous trials in women with polycystic ovary syndrome are important to address: 1 A range of diet compositions including low glycaemic index for both prevention of weight gain/weight maintenance and weight loss in women who are overweight and in women who are lean Context. Few comparative studies have explored methods to deliver diet and lifestyle interventions to improve weight loss among women with PCOS. In general populations, motivational interviewing and established behaviour techniques appear more effective than traditional education and advice. 17 2 Providing instruction, establishing self-monitoring (including self-weighing and pedometer use), time-management techniques, relapseprevention techniques, individual tailoring, engaging social support and setting goals all appear useful. Individual, group and mixed intervention, and a wide range of trained providers, including doctors, nurses, dietitians, nutritionists and exercise specialists, can deliver effective lifestyle interventions. [173] [174] [175] [176] [177] Again, in general populations, behaviour-change techniques, increased contact time with health professionals, and greater intensity and duration of behavioural intervention all generate significantly more weight loss, 178 whereas a variety of settings, including primary care and community and workplace settings, appear effective. Overall, interventions to promote changes in diet and/or exercise in adults with increased risk of DM2 or CVD are more likely to be effective if they combine intensive lifestyle interventions and sustainable behaviour-change methods. However, optimising engagement, adherence and successful outcomes in young women with PCOS remains a challenge; hence, this clinical question was prioritised during guideline development. Evidence informing the recommendations. Eight articles reporting seven RCTs of moderate 139, 152, 156, 168, 179 to high risk of bias 169, 170, 180 were identified for this question. The multidisciplinary guideline development group included evidence comparing diet compositions as different diets have inherent differences in delivery. The included studies used various diet-delivery methods/tools (and associated support mechanisms) and macronutrient diet compositions. Studies consistently involved dietitian consultation, with monitoring varying from daily 169 and weekly 156 to monthly 139, 152, 168, 179, 180 or mixed interval monitoring.
152,170
Of the diet-delivery methods used, two studies used official dietary guidelines 152, 156, 170 and three studies provided food for participants. 152, 169, 179 Of these, two used partial meal replacement. 152, 179 Other studies changed composition of whole foods. 139, 152, 156, 168, 170, 179, 180 Diet changes were made to all daily meals, except in the case of one study where only breakfast was altered. 179 Exercise was only increased in two studies. 139, 168 Other studies reported regular exercise, 152, 170 or having no change in exercise levels. 156, 179 One study offered other lifestyle support mechanisms such as menu plans, emails, newsle tters, articles, recipes, and motivational support. 152, 170 There was no difference between the diet-delivery methods for most anthropometric, QoL, and emotional wellbeing outcomes. Two studies reported differences for anthropometric outcomes, 169, 179 and another reported Figure 8 . Healthy food choices differences in an emotional wellbeing outcome; 170 however, the studies varied by the diet-delivery regimen and by degree of support. Overall, the diet-delivery approaches that were consistently reported included faceto-face advice and education about diet composition, food types and practical approaches to healthy eating, including behaviour-change techniques. The evidence from the included studies is directly generalisable to the patient population of PCOS, particularly to women over 30 years of age and who have BMI у 30 kg/m 2 . However, most of the women in the studies were Caucasian, so there may be limitations to generalising these findings to other ethnic groups. Implications of the recommendations. Face-to-face, tailored dietary advice, including education, behavioural change techniques and ongoing support should be provided to women with PCOS for weight loss in overweight women (BMI у 25 kg/m 2 ) with PCOS and for prevention of weight gain in lean women (BMI < 25 kg/m 2 ) with PCOS. Current practice is unclear. Dietary modification is the joint responsibility of all health professionals, partnering with women with PCOS, and these recommendations may result in increased referrals to allied health professionals. PCOS information to aid allied health management of PCOS has been developed (See Appendix IV in full guideline). 8 There may be resource implications due to increased consultation times and increased use of care plans. Engagement of health practitioners and financial barriers for patients may present implementation barriers.
Research recommendation
1 The types of diet delivery methods and diet support and tools that are effective -an initial study would be to have diet compositions the same and vary the delivery method or support tools between the groups 2 Comparison of the delivery methods for lifestyle interventions including comparing settings and providers.
To find a dietitian, follow the links on the Dietitians Association of Australia website: http://www.daa.asn.au.
Clinical question. In women with PCOS, are exercise interventions (compared to no exercise or different exercises) effective for improving weight loss, metabolic, reproductive, fertility, quality of life and emotional wellbeing outcomes?
Recommendations
Evidence-based recommendation 5.5a Exercise participation of at least 150 minutes per week should be recommended to all women with polycystic ovary syndrome, especially those with a body mass index у 25 kg/m 2 (overweight), given the metabolic risks of polycystic ovary syndrome and the long-term metabolic benefits of exercise. Of this, 90 minutes per week should be aerobic activity at moderate to high intensity (60%-90% of maximum heart rate) to optimise clinical outcomes. -level D Clinical practice point 5.5b Encouraging exercise is the joint responsibility of all health professionals, partnering with women with polycystic ovary syndrome. Where appropriate, referral to an exercise physiologist or specialist could be considered as part of an enhanced primary care plan. Where there are significant comorbidities, assessment for exercise participation should be undertaken by the relevant health care professionals.
Tools such as Lifescripts (http://www.health.gov.au/ lifescripts) could be used for engagement in dietary change.
Context. Exercise effectively ameliorates IR and provides an effective intervention for management of PCOS. Moderate aerobic exercise can be defined as an intensity between 50%-80% of maximum oxygen consumption or 60%-90% of maximal heart rate ( Figure 9) . 181 A single session of moderate exercise enhances glucose disposal and improves insulin sensitivity. 182 Ongoing moderate exercise, at least three to five times per week, consistently reduces DM2 risk 48,1 83 and improves CVD risk factors. 184, 185 Similarly, resistance or weight-bearing exercise alone or in combination with aerobic exercise improves health outcomes in high-risk groups. [186] [187] [188] [189] There is significant evidence to support exercise alone, independent of weight loss; 160, 190 but the intensity, type and frequency of exercise remains unclear; hence, this clinical question was prioritised during guideline development. Evidence informing the recommendations. Eight RCTs with a high risk of bias were identified by the search to answer this question. Two studies compared different exercises. 140, 191, 192 Orio and colleagues showed that 24 weeks' exercise was better than no exercise with diet for fasting glucose, insulin area under the curve (AUC), glucose-insulin AUC ratio, LDL-C, HDL-C, BMI, waisthip ratio, and waist circumference. 191 However, evidence was inconsistent among the five studies that compared exercise to no exercise. [193] [194] [195] [196] [197] Exercise was better than no exercise for triglycerides;
193 BMI (P = 0.05); 196 fasting insulin (P < 0.01); insulin AUC (P < 0.001); glucose-insulin AUC ratio (P < 0.001); highly sensitive C-reactive protein (P < 0.01); SHBG (P < 0.05); BMI (P < 0.05); waist-hip ratio (P < 0.05); 195 glucose-insulin AUC ratio (P < 0.001); systolic blood pressure (P < 0.01); and diastolic blood pressure at peak exercise (P < 0.01). 197 One study found that exercise was better for menses frequency (P = 0.04); increased ovulation rate (P = 0.03); and increased cumulative ovulation rate (P = 0.01). 164 There was no difference between aerobic exercise and aerobic-resistance exercise for percent of body fat, fat mass, fat-free mass, depression scores and PCOS-related QoL. 140, 192 Overall, although exercise has benefits for women with PCOS who are overweight, the evidence is limited, inconsistent and of low quality.
The evidence from the included studies is directly generalisable to women with PCOS who are overweight, with practical exercise regimens used. There may be limitations to generalising these findings to other ethnic groups, especially to non-European populations. Implications of the recommendations. Health care professionals can recommend 150 minutes of exercise per week based on current national and international guidelines for the general population [198] [199] [200] [201] [202] [203] [204] [205] [206] on exercise prescription for health and weight maintenance. Within this, 90 minutes of moderate-to high-intensity exercise ( Figure 9 ) can be recommended. Where there are barriers to exercise, consider involving an exercise physiologist to help with structured exercise training. For most practices, this recommendation will change usual care, reduce variation in practice and optimise exercise prescription and may result in increased referral to exercise physiologists. There may initially be extra costs to the health care system. Problems with engagement of, and adequate access to, health professionals, including insufficient consultation time with GPs, may be barriers. Drop-out from or nonadherence to exercise programs continues to be a problem, but if there is adequate allied health and clinical support, these challenges may be reduced. A shift in cultural mindset may be required to ensure clinicians and women with PCOS understand the importance of exercise in PCOS management.
Research recommendation
Further methodologically rigorous trials in women with polycystic ovary syndrome are important to help define what types, intensities and delivery methods of exercise strategies are optimal for lean and overweight women for improved clinical outcomes.
To find an exercise physiologist, follow the links on the Exercise and Sports Science Australia website (http:// www.essa.org.au). increases risks during pregnancy and should be regarded as a relative contraindication to assisted fertility.
6.1f Psychological factors should be considered and managed in infertile women with polycystic ovary syndrome, to optimise engagement and adherence with lifestyle interventions.
Context. Lifestyle therapy is deemed first line for women with PCOS, targeting prevention of weight gain and promoting weight loss where required, with significant health benefits. 6, 163, 207 Fertility rates are lower among women with a BMI у 30-32 kg/m 2 , and lifestyle intervention benefits extend well beyond fertility and include DM2 prevention. There remains inadequate highquality evidence on pregnancy outcomes with lifestyle intervention in PCOS. 163 Pharmacological therapy in cl u di ng cl o m ip he ne c it ra te , m e t fo rm i n a nd gonadotrophins are available and effective in improving fertility in women with PCOS. 208 However, there is little comparative data on the benefits of lifestyle versus pharmacological therapy in women with PCOS who are overweight or obese; hence, this clinical question was prioritised during guideline development. Evidence informing the recommendations. Ten RCTs (level II), of moderate 157, 209, 210 to high 145, 154, 155, [211] [212] [213] [214] risk of bias compared various types of lifestyle interventions (including low-carbohydrate or healthy diets, exercise programs and group sessions) to pharmacological therapy (including metformin or clomiphene citrate) among women with PCOS and a BMI у 25 kg/m 2 . There was little difference between lifestyle (diet) therapy (with or without placebo) and pharmacological therapy (with or without lifestyle [diet] therapy) for fertility outcomes. Gambineri and colleagues reported that metformin was better than placebo plus diet for menstrual pattern after 6 (P = 0.03) and 12 months (P = 0.003), 145, 211 and found a change in frequency of menstruation from baseline to 12 months (P = 0.01). Pasquali and colleagues reported that metformin plus diet was better than placebo plus diet (P < 0.05) for menstruation frequency. 154 Another study reported that lifestyle plus clomiphene citrate was better than lifestyle alone for ovulation rate and menstrual frequency (P < 0.05). 210 Adverse events were not consistently reported. Two patients had adverse events in the metformin group, 212 and
Qublan and colleagues reported that 11 women withdrew due to side effects in the metformin plus diet group. 155 Six women withdrew from the placebo plus diet group due to undefined side effects within the first 2 months of the study. 155 It is important to note that there was inconsistency in the components of lifestyle (diet) therapy, so a specific intervention cannot be recommended; however, given the similar efficacy of lifestyle and pharma colo gical therapy overall, the guideline development group deemed clear benefits in using lifestyle interventions over pharmacological interventions for firstline management of infertility among women with PCOS. Implications of the recommendations. Lifestyle management, including diet and exercise programs, should be used throughout the life span in women with PCOS to optimise health generally and to improve fertility outcomes. Pharmacological ovarian stimulation and/or assisted fertility should not be prescribed to women who are morbidly obese (BMI у 35 kg/m 2 ) unless appropriate weight loss has occurred, in accordance with the Royal Australian and New Zealand College of Obstetricians and Gynaecologists recommendations. 215 With lifestyle intervention as first line for women with PCOS who are overweight, initial therapy for infertility can be commenced in primary care. Barriers to implementation include impact on workloads in general practice, increased referral to allied health professionals and availability and funding for lifestyle programs. A shift in cultural mindset may be required to focus on lifestyle interventions, especially around prevention of weight gain. Context. Clomiphene citrate is a selective oestrogen receptor modulator with both oestrogenic and antioestrogenic properties. 216 It was first approved for management of anovulation in 1967 it has been a first-line ovulation-induction agent for over 40 years. It inhibits oestradiol receptors binding in the hypothalamus and pituitary, blocking negative feedback. This hypothalamus release from negative inhibition increases gonadotrophinreleasing hormone, which in turn increases FSH and stimulates follicular growth and ovulation. 217 Standard practice is to titrate clomiphene citrate doses up to 150 mg/day if ovulation is not achieved, at which point clomiphene citrate resistance (CCR) is reached. If ovulation is not achieved after six ovulatory cycles with clomiphene citrate, this is termed a state of clomiphene citrate failure. 218 Studies with clomiphene citrate show ovulation rates of 60%-85% and pregnancy rates of 30%-50% after six ovulatory cycles. The discrepancy between ovulation rates and pregnancy rates has been attributed to anti-oestrogenic clomiphene citrate effects. The rates of twin and triplet pregnancy with clomiphene citrate are 5%-7% and 0.3%, respectively. The incidence of ovarian hyperstimulation syndrome is less than 1%. 219 It is best to limit lifetime exposure to 12 treatment cycles, with concerns of increased risk of borderline ovarian tumours with longer exposure. 220 Comparative effectiveness of clomiphene citrate among infertile women with PCOS needs to be established, especially in light of potential risks. Evidence informing the recommendations. One highquality systematic review (level I) with low risk of bias found that clomiphene citrate was better than placebo for pregnancy rate per patient (P < 0.009) and ovulation rate per patient (P < 0.001) in women with PCOS; however, this included participants whose sensitivity to clomiphene citrate was not reported. 221 The evidence obtained from this systematic review is generalisable to the patient population in terms of age and BMI. The setting was varied and study locations included the United States and Canada. None of the studies were conducted in Australia and may not be generalisable to Indigenous populations. Implications of the recommendations. First-line clomiphene citrate therapy should be prescribed in specialist care. It should be noted that there are limitations, which differ between Australian states, in terms of which specialists are able to prescribe and monitor clomiphene citrate therapy. There may be resource implications as adequate monitoring will require additional resources. Costs to the patient of having adequate monitoring (tests and specialist visits) and accessibility to specialist care may be barriers to the use of clomiphene citrate; however, it is anticipated that increased costs will be offset by reduced multiple pregnancy-related costs.
Clinical question. In women with PCOS, is metformin effective for improving fertility outcomes?
Recommendations
Evidence-based recommendations 7.2a Metformin should be combined with clomiphene citrate to improve fertility outcomes rather than persisting with further treatment with clomiphene citrate alone in women with polycystic ovary syndrome who are clomiphene citrate resistant, anovulatory and infertile with no other infertility factors. -level A 7.2b Metformin could be used alone to improve ovulation rate and pregnancy rate in women with polycystic ovary syndrome who are anovulatory, have a body mass index р 30 kg/m 2 and are infertile with no other infertility factors.
-level B 7.2c If one is considering using metformin alone to treat women with polycystic ovary syndrome who are anovulatory, have a body mass index у 30 kg/m 2 , and are infertile with no other infertility factors, clomiphene citrate should be added to improve fertility outcomes. -level A
Context. IR leading to hyperinsulinaemia increases ovarian androgen biosynthesis and decreased SHBG synthesis, further increasing free androgens. Excess androgens and insulin cause premature follicular atresia and anovulation. These mechanistic insights have led to the use of insulin-sensitising drugs in PCOS. Metformin has been used extensively in DM2, is the most studied in PCOS, and has the most reassuring safety profile. Studies examining the reproductive effects of metformin in PCOS suggest benefits but are limited by study design. The evidence is generalisable to the patient population in terms of age and BMI and was completed in multiple countries; however, it may not be generalisable to Indigenous populations. Implications of the recommendations. Metformin should be added to clomiphene citrate in women with CCR PCOS; metformin alone could be used in women with PCOS and a BMI р 30 kg/m 2 ; and clomiphene citrate should be added to metformin for women with PCOS and a BMI у 30 kg/m 2 . This may result in a change in usual care as clinicians may now be more likely to prescribe metformin. Metformin may be associated with mild gastrointestinal adverse events and women should be informed about these. The guideline development group is not aware of resource implications or changes to the way care is organised with implementatio n of the recommendations.
One barrier may be that although metformin is listed as an unrestricted benefit on the Pharmaceutical Benefits Scheme, no application for metformin use in PCOS has been made to the Australian Therapeutic Goods Administration (TGA) and hence it is not approved for this indication. For TGA approval, industry must propose metformin for approval, and as metformin is generic and produced by many companies, it is unlikely that a company will fund and support an application to the TGA. This technical challenge is independent of effectiveness or evidence. Although use is evidence-based, patient explanation and consent is appropriate.
Research recommendation
Further methodologically rigorous trials are important to address: • Cost of either intervention for ovulation induction • Expertise required for the use of either intervention for ovulation induction
• The degree of intensive monitoring that is required for gonadotrophin therapy
• Implications of potential multiple pregnancy for gonadotrophin therapy
• Implications of the potential risk of ovarian hyperstimulation syndrome for gonadotrophin therapy
• Laparoscopic surgery in women who are overweight or obese is associated with both intra-operative and postoperative risks.
Context. Gonadotrophins are often used as second-line therapy in anovulatory PCOS women with CCR; however, there is an increased risk of multiple pregnancy and ovarian hyperstimulation syndrome. 231 A low-dose "stepup" protocol is used to reduce these risks. 232 A "stepdown" protocol can also be used 233 with similar success, but is not recommended for routine use. Despite a large body of observational evidence supporting the use of gonadotrophin therapy in anovulatory women with PCOS, 232 its comparative effectiveness needs to be evaluated using the best available evidence.
Evidence informing the recommendations. One systematic review and one RCT were identified by our search. There was no difference in effectiveness between gonadotrophins and laparoscopic ovarian surgery. The high-quality RCT (level II) with low risk of bias found that in therapy-naive women with PCOS, FSH and clomiphene citrate were similar for all fertility outcomes; 234 however, with small sample size and inadequate power, this cannot inform a recommendation in isolation.
A multicentre RCT on first-line clomiphene citrate versus gonadotrophins in therapy-naive anovulatory women with PCOS reported higher clinical pregnancy rate with gonadotrophins. Pregnancy rates with gonadotrophin therapy were almost double in the first cycle compared with clomiphene citrate. 235 However, this study is only published in abstract form, informing the guideline development group but not included in the evidence review.
The evidence is generalisable to patient populations in terms of age and BMI and applicability in Australia, but may not be relevant to Indigenous populations. Implications of the recommendations. Gonadotrophins are suitable for second-line therapy for improving infertility in women with PCOS in specialist care. The guideline development group is not aware of resource implications or barriers to implementation. Gonadotrophins appear to be as effective as laparoscopic ovarian surgery and clinical practice points should be considered in deciding between the two options.
Further methodologically rigorous trials are important to address the role of gonadotrophins in ovulation induction in polycystic ovary syndrome.
Clinical question. In women with PCOS, are aromatase inhibitors effective for improving fertility outcomes?
Recommendations
Evidence-based recommendations 7.4a Letrozole should not be first line pharmacological therapy in women with polycystic ovary syndrome who are anovulatory, and infertile, with no other infertility factors. -level B 7.4b Under caution either letrozole or anastrozole could be used if one is considering using aromatase inhibitors in women with polycystic ovary syndrome women who are clomiphene citrate resistant, anovulatory and infertile with no other infertility factors. If using letrozole, it is preferable to treat for 10 days at a dose of 2.5 mg/day. -level D Context. Aromatase inhibitors were proposed as ovulation-inducing agents in 2001. 236 Aromatase converts androgens to oestrogens, and aromatase inhibitors therefore inhibit oestrogen biosynthesis, interfering with hypothalamus/pituitary feedback, increasing FSH and causing ovarian follicle stimulation. 237 These agents theoretically avoid adverse effects of clomiphene citrate, 238,239 as they do not affect oestrogen receptors centrally or thin the endometrium. 237 Adverse effects include gastrointestinal disturbances, asthenia, hot flushes, headache and back pain. 237 The potential for teratogenic effects of letrozole has been raised, with an abstract suggesting higher risk of congenital cardia c and bone malformations in newborns. 240 However, two subsequent publications suggest that letrozole may not be associated with fetal anomalies. 241, 242 Given their current use in ovulation induction with limited data and potential adverse effects, this clinical question was prioritised by the guideline development group. Evidence informing the recommendations. Our search did not identify any studies addressing the effectiveness of letrozole as first-line therapy in PCOS (ie, letrozole versus Box 2. Metformin versus placebo in polycystic ovary syndrome (PCOS) Ovulation rates: Metformin outperformed placebo among overall women with PCOS (defined as all the women with PCOS in the relevant study or studies, regardless of body mass index [BMI] or clomiphene citrate exposure or sensitivity) (P < 0.001), among women with PCOS and with a BMI р 30 kg/m 2 (P < 0.001), with a BMI у 30 kg/m 2 (P = 0.007), 208 and among women with nonclomiphene citrate-resistant (CCR) PCOS (defined as clomiphene citrate sensitive or unknown clomiphene citrate sensitivity). 224 There was significant statistical heterogeneity among overall women with PCOS (I 2 = 69%) and among those with a BMI р 30 kg/m 2 (I 2 = 88%). Ovulation rates were similar between groups in CCR women.
Pregnancy rates: Metformin outperformed placebo among overall women with PCOS (P < 0.001), without statistical heterogeneity (I 2 = 0) and among those with a BMI р 30 kg/m 2 (P < 0.001) with little statistical heterogeneity (I 2 = 40%) 208 but no difference was noted in those with BMI у 30 kg/m 2 , in clomiphene citrate-naive women, women with CCR PCOS or women with non-CCR PCOS.
Live birth rates: There was no difference between metformin and placebo in overall women with PCOS, in women with CCR and women with a BMI у 30 kg/m 2 .
Miscarriage rates: There was no difference between metformin and placebo in overall women with PCOS.
Adverse effects: Metformin induced more gastrointestinal-related adverse events compared with placebo (P < 0.001), with little statistical heterogeneity (I 2 = 25%). Pregnancy rates: Clomiphene citrate outperformed metformin among overall women with PCOS (P = 0.018) and among those with a BMI у 30 kg/m 2 (P < 0.001). However, there was significant statistical heterogeneity seen in overall women with PCOS (I 2 = 91%). Metformin outperformed clomiphene citrate among those with a BMI р 30 kg/m 2 ; however, this was based on a single study (P = 0.003). 208 Live birth rates: Clomiphene citrate and metformin were comparable in overall women with PCOS, with statistical heterogeneity. Clomiphene citrate was better than metformin for live birth rate in those with a BMI у 30 kg/m 2 (P < 0.002) without statistical heterogeneity (I 2 = 0). Metformin outperformed clomiphene citrate in those with a BMI р 30 kg/m 2 ; however, this was based on a single study (P < 0.001). 208 Adverse effects: There was no difference in multiple pregnancy rate (without statistical heterogeneity) and miscarriage rate (with statistical heterogeneity) between metformin and clomiphene citrate in overall women with PCOS.
◆ placebo in treatment-naive patients). We identified 11 studies on letrozole as second-line therapy in PCOS. One high-quality RCT (level II) with a low risk of bias using letrozole versus placebo in PCOS with CCR, found letrozole better for ovulation rates (P = 0.006) but similar for pregnancy rate and live birth rate per patient. 243 Two RCTs (level II), one with a high risk of bias 244 and one with a low risk of bias, 245 found no difference between letrozole and anastrozole for ovulation and pregnancy rate per cycle and miscarriage rate per pregnancy among women with CCR PCOS. 245 The lower-quality study 244 found letrozole to be better; however, results should be interpreted with caution.
One high-quality RCT (level II) with low risk of bias found 10 days of letrozole better than 5 days for pregnancy rate per cycle (P = 0.03), with no differences in ovulation rate per patient and miscarriage rate per pregnancy among women with CCR PCOS. 246 Six RCTs (level II) of low, 247,248 moderate 249, 250 and high risk of bias 251, 252 compared letrozole to clomiphene citrate. Meta-analysis of these RCTs revealed that letrozole was better than clomiphene citrate for ovulation rate per patient after combining three studies (P < 0.0001) [249] [250] [251] of women with therapy-naive CCR PCOS (although some were without clarification on CCR status). Meta-analyses of two other studies showed no differences in ovulation rate per cycle 247, 248 in therapy-naive women with PCOS, 247 and women with PCOS where CCR status was not reported. 248 Further, no differences in pregnancy rate per patient, [247] [248] [249] [250] [251] miscarriage and live birth rate per pregnancy and multiple pregnancy rate per patient were noted between letrozole and clomiphene citrate. [247] [248] [249] [250] [251] One medium-quality RCT (level II) with moderate risk of bias compared letrozole to clomiphene citrate plus metformin. No difference in ovulation and pregnancy rate per cycle or miscarriage and multiple pregnancy rate per pregnancy was noted in CCR PCOS. 253 The evidence was generalisable in terms of age and BMI and studies were conducted in many nations. They may be applicable in Australia, but may not be relevant to Indigenous populations. Implications of the recommendations. We recommend caution with aromatase inhibitor use, as these agents have not been approved for use in ovulation induction in PCOS. The Pharmaceuticals Benefits Scheme does not reimburse costs and it is unlikely these agents would be first-line routine treatment in PCOS. The evidence about congenital anomalies with aromatase inhibitors is unclear and should prompt patient explanation and consent. The guideline development group is not aware of resource implications, changes to the way care is organised or barriers to implementation of these recommendations.
Research recommendations
Further methodologically rigorous trials are important to address the role of aromatase inhibitors in ovulation induction in polycystic ovary syndrome.
Further methodologically rigorous trials are important to address the impact of different ovulation induction agents in subgroups of polycystic ovary syndrome including those based on BMI.
Box 5. Metformin plus clomiphene citrate versus metformin alone in polycystic ovary syndrome (PCOS) Ovulation rates: Metformin plus clomiphene citrate was better than metformin alone among overall women with PCOS (defined as all the women with PCOS in the relevant study or studies (P < 0.001). 230 Pregnancy rates: Metformin plus clomiphene citrate was better than metformin alone among overall women with PCOS (P < 0.001). 230 Live birth rates: Metformin plus clomiphene citrate was better than metformin alone in overall women with PCOS (P < 0.001). 230 Adverse effects: There was no difference between metformin plus clomiphene citrate and metformin alone for miscarriage rate or adverse events in overall women with PCOS. ◆ Box 4. Metformin plus clomiphene citrate versus clomiphene citrate alone in polycystic ovary syndrome (PCOS) Ovulation rates: Metformin plus clomiphene citrate was better than clomiphene citrate alone among overall women with PCOS (defined as all the women with PCOS in the relevant study or studies, regardless of body mass index [BMI]) (P < 0.001) and among those with a BMI р 30 kg/m 2 (P = 0.009), with a BMI у 30 kg/m 2 (P < 0.001), with clomiphene citrate-resistant (CCR) PCOS (P < 0.001), 208 with non-CCR PCOS, 224 and where CCR status was unknown (P < 0.001). 208 However, there was significant statistical heterogeneity in these group comparisons (I 2 > 65%), except among women with CCR PCOS (I 2 = 0). There was no difference between the two treatments in women with clomiphene citrate-sensitive PCOS.
Pregnancy rates: Metformin plus clomiphene citrate was better than clomiphene citrate alone among overall women with PCOS (P = 0.006), among those with a BMI у 30 kg/m 2 (P = 0.004), 208 clomiphene citrate-naive women (P < 0.001), and women with CCR PCOS (P < 0.001). 225 There was significant statistical heterogeneity in all these group comparisons (I 2 > 58%) except among those with a BMI у 30 kg/m 2 (I 2 = 40%) and those with CCR PCOS (I 2 = 0). There was no difference between metformin plus clomiphene citrate and clomiphene citrate alone among those with a BMI р 30 kg/m 2 , non-CCR PCOS, and those with unknown clomiphene citrate sensitivity.
Live birth rates: Metformin plus clomiphene citrate was better than clomiphene citrate alone for increasing the live birth rate among women with CCR PCOS (P = 0.03), 225 Context. Laparoscopic ovarian "drilling" was first described in 1984 254 with minor variations developed subsequently; all are characterised by an altered endocrine profile following surgery. Mechanisms underpinning hormonal changes and resumption of ovulation remain poorly understood. Laparoscopic ovarian drilling in PCOS is thought
• to cause fewer adhesions than performing a laparotomy; • to be more cost-effective as an outpatient procedure; and • to restore regular mono-ovulations, albeit for a limited time in most patients.
In contrast, ovulation induction with gonadotrophins is expensive and requires regular monitoring, with risks of multiple pregnancy and ovarian hyperstimulation syndrome. The mechanisms of action, comparative effectiveness and the long-term risks of laparoscopic ovarian surgery in infertile women with PCOS still remain unclear; hence, this area has been prioritised in guideline development. Evidence informing the recommendations. Six articles reporting five studies were identified by our search to answer this question. One high-quality systematic review of RCTs (level I) with low risk of bias compared laparoscopic ovarian surgery to gonadotrophins with no differences for live birth rate, pregnancy and ovulation rate per patient and miscarriage rate per pregnancy, but laparoscopic ovarian surgery had fewer multiple pregnancies. 255 One high-quality RCT (level II) with a low risk of bias found that clomiphene citrate plus metformin was better than laparoscopic ovarian surgery for ovulation rate per cycle (P = 0.02), but there was no difference for live birth rate, pregnancy rate per cycle and miscarriage rate per pregnancy. 256 Two medium-quality RCTs (level II) with moderate risk of bias found insufficient evidence to recommend laparoscopic ovarian surgery compared with metformin for live birth rate per patient, ovulation or pregnancy rate per cycle, pregnancy rate per patient and miscarriage rate per pregnancy. [257] [258] [259] One reported laparoscopic ovarian surgery was better than metformin for ovulation (P = 0.001) and pregnancy rate per cycle and per patient (P = 0.03 and P = 0.03, respectively), 257 and the other reported metformin was better than laparoscopic ovarian surgery for pregnancy rate per cycle (P < 0.05), and miscarriage rate (P < 0.05). [258] [259] One high-quality RCT (level II) 260 and one high-quality systematic review of RCTs (level I), 255 both with low risk of bias, found that laparoscopic ovarian surgery was better than gonadotrophins for multiple pregnancy rate, 255 and that there was no difference between laparoscopic ovarian surgery and clomiphene citrate for live birth rate per patient, pregnancy rate per patient, ovulation rate per patient and miscarriage rate per pregnancy. 260 There was insufficient evidence to support or refute the use of laparoscopic ovarian surgery over either metformin or clomiphene citrate alone, or clomiphene citrate plus metformin, for multiple pregnancies, 257, 260 and there was insufficient evidence to support or refute the use of laparoscopic ovarian surgery over any intervention for adverse effects and QoL.
The evidence was from multiple countries and may be generalisable to the patient population in terms of age and BMI. The RCT 261 included in the systematic review by Farquhar and colleagues conducted in New Zealand 255 may also be generalisable to Indigenous populations. Implications of the recommendations. Laparoscopic ovarian surgery should be considered a second-line treatment indicated for infertile, anovulatory women with CCR PCOS. Laparoscopic ovarian surgery, when compared with other second-line treatments, is equally effective as gonadotrophins, with fewer multiple pregnancies. However, laparoscopic surgery, especially in overweight women, is associated with intra-operative risks (ie, difficulty with access to abdominal cavity and manipulation of surgical instruments, reduced operative field exposure) and postoperative risks (ie, bleeding, infection, thromboembolism, pulmonary atelectasis/ hypoxaemia, and wound complications). There is little research addressing the long-term complications of laparoscopic ovarian surgery. The guideline development group is not aware of changes to the way care is organised or barriers to implementation of these recommendations. Issues covered in the clinical practice point should be considered when deciding between laparoscopic ovarian surgery and gonadotrophins. Clinical practice points 8.2b If bariatric surgery is to be prescribed, the following key issues should be considered:
• A structured weight management program involving diet, physical activity and interventions to improve psychological, musculoskeletal and cardiovascular health should continue post-operatively.
• The patient should be made aware of the risk of pre-and post-operative nutritional deficiencies and should be managed in a specialist interdisciplinary care setting, including a bariatric surgeon, a dietitian and/or other multidisciplinary staff trained to work with patients who have had bariatric surgery.
8.2c
If bariatric surgery is to be prescribed, the following key issues should be considered:
• Bariatric surgery should not be conducted in patients who are known to be pregnant 262 • Pregnancy should be avoided during periods of rapid weight loss
• Patients should be counselled to avoid pregnancy for at least 12-18 months after bariatric surgery 262, 263 • Contraception should be discussed prior to surgery • If pregnancy occurs, the patient should be made aware of the risk of pre-and post-operative nutritional deficiencies and should ideally be managed in a specialist interdisciplinary care setting which includes an obstetrician, bariatric surgeon and a dietitian and/or other multidisciplinary staff trained to work with patients who have had bariatric surgery to ensure that nutritional deficiencies and complications are avoided
• Fetal growth should be monitored during pregnancy • A structured weight management program involving diet, physical activity and interventions to improve psychological, musculoskeletal and cardiovascular health should continue post-operatively.
Context. Weight loss improves fertility and addresses maternal and neonatal complications associated with obesity, potentially also increasing the safety and effectiveness of ovulation induction. Intensive lifestyle intervention should be implemented for all overweight women wishing to improve fertility. It has been suggested that women with a BMI у 35kg/m 2 after failed attempts at weight loss for more than 1 year may consider bariatric surgery; however, surgical studies are generally poorly designed, 264 and the 2009 American College of Obstetrics and Gynecology clinical practice guidelines do not currently recommend bariatric surgery for fertility treatment. 265 A recent meta-analysis of bariatric surgery in general populations reports weight loss of 38.5 kg or 56% excess weight loss and resolution of DM2 in 78% of patients with DM2. 266 General international obesity guidelines 267 recommended consideration of bariatric surgery with a BMI у 35 kg/m 2 and one or more complications, which are expected to abate with weight reduction, after failure of a structured lifestyle intervention. Surgery can be considered after unsuccessful lifestyle intervention with a BMI у 40 kg/m 2 and can be first line with BMI у 50 kg/m 2 . 268 Bariatric surgery has significant complications, including malabsorptive states, psychological issues, poor nutritional status, and disordered eating. Eating disorders are already relatively common among women with PCOS. Also, nutritional impact in pregnancy is unclear and although supplement use is widely recommended following bariatric surgery and for pregnant women, poor compliance is a problem. 269 Specifically with regards to PCOS, recent guidelines f ro m t h e A m e r i c a n A s s o c i a t i o n o f C l i n i c a l Endocrinologists and the Obesity Society and the American Society for Metabolic and Bariatric Surgery noted a lack of conclusive clinical PCOS-specific evidence and suggested they should be advised that fertility status may be improved postoperatively. 270 Overall, among people with morbid obesity, lifestyle interventions have very limited efficacy, but given the substantial efficacy of bariatric surgery for women who are severely obese, including in women with PCOS, it is important to determine the impact of bariatric surgery on infertility in women with PCOS. Benefits need to be balanced with risks of bariatric surgery, and controversies, including whether PCOS is considered an obesity-related condition and may reduce BMI cut-offs, 271 need to be addressed. 270 In this context, these issues were prioritised during guideline development. Evidence informing the recommendations. We did not identify any PCOS-specific evidence to inform this re c om m en d a t i o n a n d a c l i n i c a l c on se n s u s recommendation has been made using the clinical expertise of the multidisciplinary guideline development group, informed by existing evidence-based clinical guidelines for bariatric surgery in the general population. In general populations, bariatric surgery is recommended for individuals with a BMI у 35 kg/m 2 and the presence of comorbid conditions that are expected to improve significantly with weight reduction. 267, 270 PCOS is a comorbid condition that improves significantly with weight reduction and is strongly associated with other comorbidities including DM2 and increased CVD risk. Therefore, it was concluded that general population evidence-based recommendations for bariatric surgery are applicable to this evidence review and patient population. Implications of the recommendations. Bariatric surgery could be considered second-line therapy to improve fertility outcomes in PCOS. Current practice is unclear, although few women with PCOS are likely to be having this surgery. Implementation of the recommendations has resource implications including the cost of surgery and Supplement specialist care, potentially offset by less use of assisted reproductive technologies and fewer complications in pregnancy and beyond. Ethnic differences in obesity and complications are recognised and cut-off points for surgery may need to be adjusted for those at high risk. It is important to note that women with PCOS who become pregnant after bariatric surgery could be considered to have high-risk pregnancies, as are women in the general population who are obese and pregnant.
Research recommendation
Further methodologically rigorous trials are important to address the efficacy, safety and role of bariatric surgery in polycystic ovary syndrome including improving fertility.
Limitations of the guideline
Given the complexity of PCOS, it was beyond the resources, time frames and scope of this guideline to address all aspects of this condition and the questions addressed here reflect a development and prioritisation process described in the full guideline.
8 Generally in PCOS, there is a paucity of evidence and the evidence that is available is of poor quality; hence, consensus recommendations informed by evidence in other similar conditions often underpinned recommendations in this guideline. This guideline does not seek to provide full safety and usage information on pharmacological and surgical interventions. The pharmacological and surgical interventions recommended in the guideline should not be applied without consideration to the patient's clinical profile and personal preferences. It is recommended that the reader consults the full guideline, 8 the Therapeutic Guidelines (http://www.tg.com.au) and the National Prescribing Service (http://www.nps.org.au) for detailed prescribing information.
A formal analysis of cost-effectiveness was not completed. Consideration was given to cost in guideline development group meetings and impacted on recommendations. The guideline is based on the best evidence available up to November 2010. Development of technology and pharmacological intervention progresses rapidly. To ensure the guideline is updated appropriately, new significant publications will be inserted promptly if they have bearing on safety or if changes occur in the TGA registration status.
All recommendations are limited by their applicability and generalisability, therefore clinical judgement remains important. Finally, a guideline is only useful if it has been translated and implemented into practice appropriately. In doing so, cultural barriers may be experienced. 
